Oppenheimer Reiterates Outperform Rating, $12 PT on Trius Therapeutics on 4Q12 EPS

Loading...
Loading...
In a report published Wednesday, Oppenheimer analyst Angad Verma reiterated his Outperform rating and $12.00 price target on Trius Therapeutics
TSRX
. In the report, Verma noted, “On 3/12, TSRX reported 4Q12 EPS of ($0.36), above our ($0.54) forecast, owing to higher revenues of $5.2M (vs. our $2.9M estimate) and lower operating expenses of $21.1 (vs. our $24.2M estimate). Most important, we anticipate an imminent top-line readout, likely by the end of March, from Tedizolid's phase III ESTABLISH-2 study and a subsequent NDA filing during 2H13 (suggesting potential approval in 1H14). We believe TSRX will initiate a Phase III study in lung infections in 2H13 (we previously expected 1H13), suggesting potential approval in the lung in ~2016. We are adjusting, estimates to reflect revised operating expense expectations.” Trius Therapeutics closed on Tuesday at $6.21.
Posted In: Analyst ColorReiterationAnalyst RatingsOppenheimer
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...